Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Look to the east before sunrise on June 22 to catch the delicate form of the crescent moon shining with Venus alongside the Pleiades star cluster.

This study introduces a valuable spring-bead model for epithelial cell layers, designed to improve previous cell-resolved approaches and to understand the connection between the biophysics of ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

This stock is Vertex Pharmaceuticals (VRTX-1.65%), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF) treatment market.

The love triangle in "Brooklyn" doesn't just see a woman have to choose between two men, but two countries. Saoirse Ronan plays Eilis, an Irish immigrant in 1950s New York who falls for an Italian ...

Throughout the last three months, 10 analysts have evaluated Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...